<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11531245</article-id><article-id pub-id-type="pmc">2364119</article-id><article-id pub-id-type="pii">6692010</article-id><article-id pub-id-type="doi">10.1054/bjoc.2001.2010</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pivot</surname><given-names>X</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Raymond</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Laguerre</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Degardin</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Cals</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Armand</surname><given-names>J P</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lefebvre</surname><given-names>J L</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Gedouin</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ripoche</surname><given-names>V</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Kayitalire</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Niyikiza</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Johnson</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Latz</surname><given-names>J</given-names></name></contrib><contrib contrib-type="author"><name><surname>Schneider</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Centre Antoine Lacassagne, Nice, France</aff><aff id="aff2"><label>2</label>Institut Gustave Roussy, Villejuif, France</aff><aff id="aff3"><label>3</label>Centre Eug&#x000e8;ne Marquis, Rennes, France</aff><aff id="aff4"><label>4</label>Institut Oscar Lambret, Lille, France</aff><aff id="aff5"><label>5</label>Hopital Font-pr&#x000e9;, Toulon, France</aff><aff id="aff6"><label>6</label>Eli Lilly and Company, SA, France</aff><aff id="aff7"><label>7</label>Eli Lilly and Company, Indianapolis, IN, USA</aff><pub-date pub-type="ppub"><month>09</month><year>2001</year></pub-date><volume>85</volume><issue>5</issue><fpage>649</fpage><lpage>655</lpage><history><date date-type="received"><day>28</day><month>11</month><year>2000</year></date><date date-type="rev-recd"><day>20</day><month>04</month><year>2001</year></date><date date-type="accepted"><day>04</day><month>07</month><year>2001</year></date></history><copyright-statement>Copyright 2001, Cancer Research Campaign</copyright-statement><copyright-year>2001</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>This phase II study determined response rate of patients with locally advanced or metastatic head and neck cancer treated with pemetrexed disodium, a new multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase and glycinamide ribonucleotide formyl transferase. 35 patients with local or metastatic relapse of squamous cell carcinoma of the head and neck (31 male, 4 female; median age 53 years) were treated with pemetrexed 500&#x02008;mg&#x02008;m<sup>2</sup> administered as a 10-minute infusion on day 1 of a 21-day cycle. Patients received 1 to 8 cycles of therapy. 9 patients (26.5&#x00025;) had an objective response, with a median response duration of 5.6 months (range 2.9&#x02013;20 months). 15 (44.1&#x00025;) had stable disease, and 8 (23.5&#x00025;) had progressive disease. 2 patients were not assessable for response. Median overall survival was 6.4 months (range 0.7&#x02013;28.1 months; 95&#x00025; CI: 3.9&#x02013;7.7 months). 24 patients (68.6&#x00025;) experienced grade 3/4 neutropenia, with febrile neutropenia in 4 (11.4&#x00025;). Grade 3/4 anaemia and thrombocytopenia occurred in 11 (34.3&#x00025;) and 6 (17.1&#x00025;) patients, respectively. The most frequent non-haematological toxicity was grade 3/4 mucositis (17.1&#x00025;; 6 patients). In conclusion, pemetrexed is active in squamous cell carcinoma of the head and neck. Although substantial haematological toxicities were experienced by patients, subsequent studies have shown that these toxicities can be proactively managed by folic acid and vitamin B<sub>12</sub> supplementation. &#x000a9; 2001 Cancer Research Campaign <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.bjcancer.com">http://www.bjcancer.com</ext-link></p></abstract><kwd-group><kwd>LY231514</kwd><kwd>pemetrexed disodium</kwd><kwd>ALIMTA&#x000ae;</kwd><kwd>multitargeted antifolate</kwd><kwd>head and neck squamous cell carcinoma</kwd><kwd>chemotherapy</kwd></kwd-group></article-meta></front></article>


